[Isotretinoin (Roaccutane) in women of childbearing age: failure of following prescription guidelines].
BACKGROUND
Despite prominent warnings, pregnancies continue to be reported in women exposed to isotretinoin.


METHODS
We report results of the analysis of 318 questions asked to pharacovigilance structures in France from 1987 to 1995 because of an exposition to isotretinoin during the risk period and of a prospective inquiry concerning isotretinoin prescription in women conducted among pharmacists.


RESULTS
These 318 pregnancies began during the month after Roaccutane withdrawal (n = 104, 33 p. 100), during Roaccutane treatment (n = 163, 51 p. 100) or before Roaccutane treatment (n = 51, 16 p. 100). Of the 267 women with pregnancies conceived during treatment with isotretinoin (n = 104) or during the month after its discontinuation (n = 163), contraception was not prescribed in 28 (15 p. 100) or prescribed but with poor compliance in 109 (60 p. 100). Pregnancy was terminated voluntarily in 199 women (81 p. 100). In the 173 women who were interviewed in pharmacies, 49 (28 p. 100) did not use contraception and among them contraception was prescribed in only 59 p. 100. Only 14 p. 100 had received full information about isotretinoin and pregnancy. The teratogenic effects of isotretinoin were known by 98 p. 100 of the women and the need of contraception during treatment and for one month after discontinuation by 70 p. 100.


CONCLUSIONS
Insufficient compliance with warnings is the main reason for pregnancies in women receiving isotretinoin therapy. A pregnancy prevention program is needed before prescription to ensure comprehension and to obtain informed consent of patients.
Autret
E
E
Service de Pharmacologie Clinique, Hôpital Bretonneau, Tours.
Radal
M
M
Jonville-Béra
A P
AP
Goehrs
J M
JM
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D000293:Adolescent; D000328:Adult; D000075202:Contraindications; D011307:Drug Prescriptions; D005260:Female; D006306:Health Surveys; D006801:Humans; D015474:Isotretinoin / Q000009:adverse effects*; D007641:Keratolytic Agents / Q000009:adverse effects*; D010349:Patient Compliance; D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D012307:Risk Factors; D013723:Teratogens
D007641:Keratolytic Agents; D013723:Teratogens; D015474:Isotretinoin